Lindh Jonatan D, Annas Anita, Meurling Lennart, Dahl Marja-Liisa, AL-Shurbaji Ayman
Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden.
Eur J Clin Pharmacol. 2003 Sep;59(5-6):401-6. doi: 10.1007/s00228-003-0627-x. Epub 2003 Jul 25.
To study the influence of CYP3A4 inhibition by ketoconazole on the disposition of venlafaxine in individuals with different CYP2D6 pheno- and genotypes.
In an open two-phase study, 21 healthy volunteers with known CYP2D6 pheno- and genotype [14 extensive metabolisers (EMs), 7 poor metabolisers (PMs)] were given a single oral dose of venlafaxine (50 mg to EMs and 25 mg to PMs). Plasma and urine levels of venlafaxine and its three metabolites were measured and the pharmacokinetics of venlafaxine were determined. After a 2-week washout period, subjects were treated for 2 days with ketoconazole (100 mg twice daily) starting 1 day before the administration of venlafaxine; and the same parameters as for the administration of venlafaxine only were measured.
Data were evaluated from 20 subjects (14 EMs and 6 PMs) who completed the study. The dose-corrected AUC of venlafaxine was on average 2.3 times higher ( P<0.01) and that of its active metabolite O-desmethylvenlafaxine 3.4 times lower ( P<0.0001) in PMs than EMs. There was a good correlation between the debrisoquine metabolic ratio and the ratio between the AUC of venlafaxine and that of O-desmethylvenlafaxine ( Rs=0.93, P<0.002). The majority of subjects showed higher plasma levels of venlafaxine and O-desmethylvenlafaxine upon co-administration of ketoconazole. AUC of venlafaxine significantly increased by 36% and that of O-desmethylvenlafaxine by 26% ( P<0.01). C(max) values increased by 32% and 18%, respectively. The elimination half-life of venlafaxine was unaltered. Three of the PMs displayed marked increases in AUC (81, 126 and 206%) and C(max) (60, 72, 119%) of venlafaxine while the other three showed small or no changes.
Ketoconazole consistently affected the disposition of venlafaxine in EMs of debrisoquine while the response in PMs was erratic. The precise mechanisms underlying this interaction remain to be elucidated.
研究酮康唑对细胞色素P450 3A4(CYP3A4)的抑制作用对不同细胞色素P450 2D6(CYP2D6)表型和基因型个体中venlafaxine处置的影响。
在一项开放的两阶段研究中,21名已知CYP2D6表型和基因型的健康志愿者[14名快代谢者(EMs),7名慢代谢者(PMs)]口服单剂量venlafaxine(EMs服用50mg,PMs服用25mg)。测定venlafaxine及其三种代谢物的血浆和尿液水平,并确定venlafaxine的药代动力学。在2周的洗脱期后,受试者在venlafaxine给药前1天开始用酮康唑(每日2次,每次100mg)治疗2天;并测量与仅给予venlafaxine时相同的参数。
对完成研究的20名受试者(14名EMs和6名PMs)的数据进行了评估。与EMs相比,PMs中venlafaxine的剂量校正AUC平均高2.3倍(P<0.01),其活性代谢物O-去甲基venlafaxine的剂量校正AUC低3.4倍(P<0.0001)。去甲异喹胍代谢率与venlafaxine和O-去甲基venlafaxine的AUC比值之间存在良好的相关性(Rs=0.93,P<0.002)。大多数受试者在联合使用酮康唑时显示venlafaxine和O-去甲基venlafaxine的血浆水平较高。venlafaxine的AUC显著增加36%,O-去甲基venlafaxine的AUC增加26%(P<0.01)。C(max)值分别增加32%和18%。venlafaxine的消除半衰期未改变。3名PMs中venlafaxine的AUC(分别增加81%、126%和206%)和C(max)(分别增加60%、72%和119%)显著增加而其他3名PMs变化很小或无变化。
酮康唑持续影响去甲异喹胍快代谢者中venlafaxine的处置,而慢代谢者中的反应不稳定。这种相互作用的精确机制仍有待阐明。